Gene:
PPARA
peroxisome proliferator-activated receptor alpha

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for PPARA

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs135543 NC_000022.10:g.46555321T>C, NC_000022.11:g.46159422C>T, NG_012204.1:g.13823T=, NG_012204.1:g.13823T>C, NM_001001928.2:c.-43+7448C>T, NM_001001928.2:c.-43+7448T>C, NM_005036.4:c.-127+7448C>T, NM_005036.4:c.-127+7448T>C, XM_005261653.1:c.-43+7448T>C, XM_005261654.1:c.-40+7448T>C, XM_005261655.1:c.-127+7448T>C, XM_005261655.2:c.-127+7452C>T, XM_006724269.2:c.-124+7452C>T, XM_006724270.2:c.-40+7452C>T, XM_011530239.1:c.-224+7452C>T, XM_011530240.1:c.-227+7452C>T, XM_011530241.1:c.-140+7452C>T, XM_011530244.1:c.-633+7452C>T, XM_011530245.1:c.-449+7452C>T, XR_244379.1:n.181+7448T>C, XR_937869.1:n.189+7452C>T, XR_937870.1:n.188+7452C>T, rs17248110, rs5767347, rs59629438
T > C
SNP
No VIP available CA VA
rs135550 NC_000022.10:g.46553234C>T, NC_000022.11:g.46157339T>C, NG_012204.1:g.11736C=, NG_012204.1:g.11736C>T, NM_001001928.2:c.-43+5361C>T, NM_001001928.2:c.-43+5361T>C, NM_005036.4:c.-127+5361C>T, NM_005036.4:c.-127+5361T>C, XM_005261653.1:c.-43+5361C>T, XM_005261654.1:c.-40+5361C>T, XM_005261655.1:c.-127+5361C>T, XM_005261655.2:c.-127+5369T>C, XM_006724269.2:c.-124+5369T>C, XM_006724270.2:c.-40+5369T>C, XM_011530239.1:c.-224+5369T>C, XM_011530240.1:c.-227+5369T>C, XM_011530241.1:c.-140+5369T>C, XM_011530244.1:c.-633+5369T>C, XM_011530245.1:c.-449+5369T>C, XR_244379.1:n.181+5361C>T, XR_937869.1:n.189+5369T>C, XR_937870.1:n.188+5369T>C, rs57651164, rs5767340
C > T
SNP
No VIP available No Clinical Annotations available VA
rs135561 NC_000022.10:g.46539639A>G, NC_000022.11:g.46143764G>A, rs5769024, rs60813550
A > G
SNP
No VIP available CA VA
rs149711321 NC_000022.10:g.46594035T>C, NC_000022.11:g.46198138T>C, NG_012204.1:g.52537T>C, NM_001001928.2:c.-42-204T>C, NM_005036.4:c.-42-204T>C, XM_005261653.1:c.-42-204T>C, XM_005261654.1:c.-39-207T>C, XM_005261655.1:c.-42-204T>C, XM_005261655.2:c.-42-204T>C, XM_005261656.1:c.-39-207T>C, XM_005261656.2:c.-39-207T>C, XM_005261657.1:c.-42-204T>C, XM_005261658.1:c.-39-207T>C, XM_006724269.2:c.-39-207T>C, XM_006724270.2:c.-39-207T>C, XM_011530239.1:c.-39-207T>C, XM_011530240.1:c.-42-204T>C, XM_011530241.1:c.-39-207T>C, XM_011530242.1:c.-42-204T>C, XM_011530243.1:c.-42-204T>C, XM_011530244.1:c.-448-204T>C, XM_011530245.1:c.-448-204T>C, XR_244379.1:n.182-204T>C, XR_937869.1:n.274-204T>C, XR_937870.1:n.273-204T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1800206 NC_000022.10:g.46614274C>G, NC_000022.11:g.46218377C>G, NG_012204.1:g.72776C>G, NM_001001928.2:c.484C>G, NM_005036.4:c.484C>G, NP_001001928.1:p.Leu162Val, NP_005027.2:p.Leu162Val, XM_005261653.1:c.484C>G, XM_005261654.1:c.484C>G, XM_005261655.1:c.484C>G, XM_005261655.2:c.484C>G, XM_005261656.1:c.484C>G, XM_005261656.2:c.484C>G, XM_005261657.1:c.484C>G, XM_005261658.1:c.484C>G, XM_006724269.2:c.484C>G, XM_006724270.2:c.484C>G, XM_011530239.1:c.484C>G, XM_011530240.1:c.484C>G, XM_011530241.1:c.484C>G, XM_011530242.1:c.484C>G, XM_011530243.1:c.484C>G, XM_011530244.1:c.78C>G, XM_011530245.1:c.78C>G, XP_005261710.1:p.Leu162Val, XP_005261711.1:p.Leu162Val, XP_005261712.1:p.Leu162Val, XP_005261713.1:p.Leu162Val, XP_005261714.1:p.Leu162Val, XP_005261715.1:p.Leu162Val, XP_006724332.1:p.Leu162Val, XP_006724333.1:p.Leu162Val, XP_011528541.1:p.Leu162Val, XP_011528542.1:p.Leu162Val, XP_011528543.1:p.Leu162Val, XP_011528544.1:p.Leu162Val, XP_011528545.1:p.Leu162Val, XP_011528546.1:p.Ala26=, XP_011528547.1:p.Ala26=, XR_244379.1:n.707C>G, XR_937869.1:n.799C>G, XR_937870.1:n.798C>G, rs17248699, rs4253796, rs59477602
C > G
SNP
L162V
No VIP available CA VA
rs4253728 NC_000022.10:g.46610067G>A, NC_000022.11:g.46214170G>A, NG_012204.1:g.68569G>A, NM_001001928.2:c.209-1003G>A, NM_005036.4:c.209-1003G>A, XM_005261653.1:c.209-1003G>A, XM_005261654.1:c.209-1003G>A, XM_005261655.1:c.209-1003G>A, XM_005261655.2:c.209-1003G>A, XM_005261656.1:c.209-1003G>A, XM_005261656.2:c.209-1003G>A, XM_005261657.1:c.209-1003G>A, XM_005261658.1:c.209-1003G>A, XM_006724269.2:c.209-1003G>A, XM_006724270.2:c.209-1003G>A, XM_011530239.1:c.209-1003G>A, XM_011530240.1:c.209-1003G>A, XM_011530241.1:c.209-1003G>A, XM_011530242.1:c.209-1003G>A, XM_011530243.1:c.209-1003G>A, XM_011530244.1:c.-198-1003G>A, XM_011530245.1:c.-198-1003G>A, XR_244379.1:n.432-1003G>A, XR_937869.1:n.524-1003G>A, XR_937870.1:n.523-1003G>A, rs17242080, rs56473198, rs56722050
G > A
SNP
No VIP available CA VA
rs4253778 NC_000022.10:g.46630634G>C, NC_000022.11:g.46234737G>C, NG_012204.1:g.89136G>C, NM_001001928.2:c.1160-396G>C, NM_005036.4:c.1160-396G>C, XM_005261653.1:c.1160-396G>C, XM_005261654.1:c.1160-396G>C, XM_005261655.1:c.1160-396G>C, XM_005261655.2:c.1160-396G>C, XM_005261656.1:c.1160-396G>C, XM_005261656.2:c.1160-396G>C, XM_005261657.1:c.1160-396G>C, XM_005261658.1:c.1160-396G>C, XM_006724269.2:c.1160-396G>C, XM_006724270.2:c.1160-396G>C, XM_011530239.1:c.1160-396G>C, XM_011530240.1:c.1160-396G>C, XM_011530241.1:c.1160-396G>C, XM_011530242.1:c.1160-396G>C, XM_011530243.1:c.1160-396G>C, XM_011530244.1:c.758-396G>C, XM_011530245.1:c.758-396G>C, XR_244379.1:n.1184-396G>C, XR_937869.1:n.1276-396G>C, XR_937870.1:n.1271-396G>C, rs17248629, rs57323063, rs61046783
G > C
SNP
No VIP available CA VA
rs4823613 NC_000022.10:g.46598307A>G, NC_000022.11:g.46202410A>G, NG_012204.1:g.56809A>G, NM_001001928.2:c.208+3819A>G, NM_005036.4:c.208+3819A>G, XM_005261653.1:c.208+3819A>G, XM_005261654.1:c.208+3819A>G, XM_005261655.1:c.208+3819A>G, XM_005261655.2:c.208+3819A>G, XM_005261656.1:c.208+3819A>G, XM_005261656.2:c.208+3819A>G, XM_005261657.1:c.208+3819A>G, XM_005261658.1:c.208+3819A>G, XM_006724269.2:c.208+3819A>G, XM_006724270.2:c.208+3819A>G, XM_011530239.1:c.208+3819A>G, XM_011530240.1:c.208+3819A>G, XM_011530241.1:c.208+3819A>G, XM_011530242.1:c.208+3819A>G, XM_011530243.1:c.208+3819A>G, XM_011530244.1:c.-199+3819A>G, XM_011530245.1:c.-199+3819A>G, XR_244379.1:n.431+3819A>G, XR_937869.1:n.523+3819A>G, XR_937870.1:n.522+3819A>G, rs5767571, rs58091507, rs74281148
A > G
SNP
No VIP available CA VA
rs9626730 NC_000022.10:g.46562183T>C, NC_000022.11:g.46166284T>C, NG_012204.1:g.20685T>C, NM_001001928.2:c.-43+14310T>C, NM_005036.4:c.-126-10467T>C, XM_005261653.1:c.-43+14310T>C, XM_005261654.1:c.-40+14310T>C, XM_005261655.1:c.-126-10467T>C, XM_005261655.2:c.-126-10469T>C, XM_006724269.2:c.-123-10469T>C, XM_006724270.2:c.-40+14314T>C, XM_011530239.1:c.-223-10469T>C, XM_011530240.1:c.-226-10469T>C, XM_011530241.1:c.-140+14314T>C, XM_011530244.1:c.-632-10469T>C, XM_011530245.1:c.-449+14314T>C, XR_244379.1:n.181+14310T>C, XR_937869.1:n.190-10469T>C, XR_937870.1:n.189-10469T>C, XR_938315.1:n.249-4962A>G, rs11090773, rs35718056, rs52826906
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  PPAR
Alternate Symbols:  NR1C1; hPPAR
PharmGKB Accession Id: PA280

Details

Cytogenetic Location: chr22 : q13.31 - q13.31
GP mRNA Boundary: chr22 : 46546458 - 46639653
GP Gene Boundary: chr22 : 46536458 - 46642653
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to PPARA: 23

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes research and clinical practice. 2016. Leonard Charles E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature reviews. Clinical oncology. 2015. Brown Sherry-Ann, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PPARA gene and phenprocoumon: a new predictor of response variability. Pharmacogenetics and genomics. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Therapeutic drug monitoring. 2014. Bruckmueller Henrike, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clinical pharmacology and therapeutics. 2014. Tsamandouras N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients. Pharmacogenetics and genomics. 2014. Kurzawski Mateusz, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Variants in Transcription Factors Associate with the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical pharmacology and therapeutics. 2014. Goswami Srijib, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European journal of clinical pharmacology. 2014. Lunde Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-alpha are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenetics and genomics. 2013. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenomics. 2013. de Keyser Catherine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARalpha). Molecular pharmacology. 2013. Thomas Maria, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics. 2013. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 3A4*22, PPAR-alpha, and ARNT polymorphisms and clopidogrel response. Clinical pharmacology : advances and applications. 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. The pharmacogenomics journal. 2012. Frazier-Wood A C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A PPARalpha promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PloS one. 2010. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology. 2009. Xie Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes. Pharmacogenetics and genomics. 2008. Knouff Christopher W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PloS one. 2009. Wray Jessica A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Journal of lipid research. 2007. Valasek Mark A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004. Foucher Christelle, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 2002. Brisson Diane, et al. PubMed

LinkOuts

NCBI Gene:
5465
OMIM:
170998
UCSC Genome Browser:
NM_005036
RefSeq RNA:
NM_001001928
NM_005036
RefSeq Protein:
NP_001001928
NP_005027
RefSeq DNA:
NG_012204
NT_011520
UniProtKB:
PPARA_HUMAN (Q07869)
Ensembl:
ENSG00000186951
GenAtlas:
PPARA
GeneCard:
PPARA
MutDB:
PPARA
ALFRED:
LO054801S
HuGE:
PPARA
Comparative Toxicogenomics Database:
5465
ModBase:
Q07869
HumanCyc Gene:
HS02075
HGNC:
9232

Common Searches